Atea Pharmaceuticals, Inc. (AVIR) company profile
Close on Nov 17, 2026Market cap $317.61MP/E –Yield –
About Atea Pharmaceuticals
Pharmaceutical Preparations, SIC 2834
The company is a clinical-stage biopharmaceutical organization focused on discovering, developing, and commercializing orally administered antiviral therapies for serious viral conditions. Utilizing a proprietary nucleos(t)ide platform, it designs candidate treatments targeting single-stranded ribonucleic acid viruses. Its leading pipeline asset is a combination regimen of bemnifosbuvir and ruzasvir, currently evaluated in late-stage clinical trials for treating hepatitis C virus infections across multiple genotypes. Additionally, the business is advancing AT-587, an oral antiviral candidate intended to treat chronic hepatitis E virus infections, specifically targeting immunocompromised patient populations who currently lack approved targeted therapeutic options.
The enterprise conducts its clinical development activities on an international scale, running late-stage clinical trial programs with sites located across the United States, Canada, and various countries outside of North America. Its global studies evaluate diverse geographic populations to encompass a broad array of viral genotypes. While the excerpt mentions company staff monitoring these multinational trials under the name Atea, the provided text does not disclose a specific headquarters location.
Summary of the business section of Atea Pharmaceuticals's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Atea Pharmaceuticals, Inc.
- Headquarters
- Boston, MA
- Address
- 225 Franklin Street, Suite 2100 02110
- Phone
- (857) 284-8891
- Website
- ateapharma.com
- Employees
- 55, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Massachusetts
- Fiscal year ends
- December 31
- Auditor
- KPMG LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- AVIR
- Exchange
- Nasdaq
- IPO date
- Oct 30, 2020
- Shares outstanding
- 80M, Aug 10, 2026
- Public float
- $262.60M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1593899
- CUSIP
- 04683R106
- ISIN
- US04683R1068
- FIGI
- BBG00TZNCJ75
- Share class FIGI
- BBG00TZNCJ84
- EIN
- 46-0574869
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Jean-Pierre Sommadossi | President, CEO, and Chairman, Director | 6,633,855 |
| Andrea Corcoran | See Remarks | 823,576 |
| Janet MJ Hammond | Chief Development Officer | 127,665 |
| Wayne Foster | EVP, Chief Accounting Officer | 91,461 |
| Maria Arantxa Horga | Chief Medical Officer | 112,159 |
| John Vavricka | Chief Commercial Officer | 176,672 |
| Jerome M. Adams | Director | 92,350 |
| Arthur S. Kirsch | Director | 45,710 |
| Howard Berman | Director | – |
| Franklin M. Berger | Director | 536,097 |
| Barbara Gayle Duncan | Director | 92,350 |
| Bruno Lucidi | Director | 142,350 |
| Bruce Polsky | Director | 124,806 |
| Polly A. Murphy | Director | 133,040 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $3.40M | $3.60M | $1.57M | $9 | $125 |
| FY2024 | $4.20M | $4.30M | $1.83M | $8 | $93 |
| FY2023 | $5.93M | $3.40M | $1.86M | $7 | $94 |
| FY2022 | $5.88M | $705.20K | $1.86M | $12 | $90 |
| FY2021 | $34.10M | -$1.46M | $8.02M | $21 | $100 |
| FY2020 | $2.89M | $15.19M | $2.93M | $138 | $116 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Jean-Pierre Sommadossi President, Chief Executive Officer and Chairman of the Board | $703.49K | $1.32M | $962.37K | $422.09K | – | $3.40M | -19% |
| Andrea Corcoran Chief Financial Officer, Executive Vice President, Legal | $549.53K | $442.17K | $437.44K | $247.29K | $14.00K | $1.69M | -12% |
| Janet Hammond Chief Development Officer | $590.89K | $459.00K | $437.44K | $265.90K | $14.00K | $1.77M | -18% |
| Maria Arantxa Horga Chief Medical Officer | $523.64K | $425.03K | $421.69K | $209.46K | $14.00K | $1.59M | -14% |
| John Vavricka Chief Commercial Officer | $443.17K | $292.84K | $290.46K | $177.27K | $14.00K | $1.22M | -12% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Oct 30, 2020
- Offer price
- $24.00
- Securities offered
- 12,500,000
- Gross proceeds
- $300.00M
- Exchange
- Nasdaq
- First trading day
- Oct 30, 2020
- First-day close
- $30.34+26.4%
- Lock-up ends (est.)
- Apr 28, 2021
“The initial public offering price of our common stock is $24.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of March 4, 2026, we had 55 full-time employees, including 19 employees with M.D., Ph.D.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Oct 30, 2020 | IPO | Initial public offering priced (424B4 prospectus) |
| Oct 26, 2020 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?